Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and…
Affinivax, Inc. a clinical stage biotechnology company with its novel MAPS technology platform for vaccines and immunotherapies, announced the completion of a $120 million Series B…
Read More...
Read More...
